Argenica Therapeutics Ltd
Research Argenica Therapeutics Ltd (AGN) on Bullrun: market cap AUD 16.70M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGN
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 16.70M
- Financial periodFY2025
- Net income-AUD 7.17M
- Free cash flow-AUD 5.70M
Valuation Snapshot
latest market cap is AUD 16.70M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 7.17M | -AUD 5.70M | n/a | -0.06 | AUD 10.56M | n/a | AUD 7.24M |
| FY2024 | n/a | -AUD 5.48M | -AUD 5.06M | n/a | -0.05 | AUD 15.91M | n/a | AUD 13.95M |
| FY2023 | n/a | -AUD 4.82M | -AUD 3.30M | n/a | -0.06 | AUD 9.29M | n/a | AUD 7.67M |
| FY2022 | n/a | -AUD 4.09M | -AUD 3.36M | n/a | -0.06 | AUD 8.91M | n/a | AUD 8.31M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-07 | AUD 16.70M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Argenica Therapeutics Ltd
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Argenica Therapeutics Ltd's market cap?
Argenica Therapeutics Ltd's market capitalization is AUD 16.70M.
What does Argenica Therapeutics Ltd do?
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.